Early data from Moderna Inc.’s COVID-19 vaccine – the first to be tested in the United States – showed that it produced protective antibodies in a small group of healthy volunteers, the company said.
BioSpace provided an update on recent personnel movement within the healthcare industry, including Cheryl R. Blanchard being named president and chief executive officer of Anika Therapeutics.
Bolt Biotherapeutics Inc., a private clinical-stage biotechnology company, tapped Edith Perez, M.D., as chief medical officer.
Recent personnel updates within the healthcare industry include Foundation Medicine veteran Thomas Civik being named president and chief executive officer of Five Prime Therapeutics.
Mirati Therapeutics made several changes to the executive management team as the company continues to accelerate the development of its KRAS and sitravatinib programs through registrational trials and prepares for commercialization.
Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.
BioNTech will acquire Neon Therapeutics Inc. in an all-stock transaction valued at approximately $67 million.
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.
Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.